Longdom Conferences

Speaker

November 23, 2020    New York, USA

Webinar on Oncology and Cancer Therapy

Dr Morganna Vance

Dr Morganna Vance

New York, USA

Title: Combination Targeted and Immunotherapies in Solid Tumor Brain Metastases

Abstract:

An estimated 20% of all patients with cancer will develop brain metastases, with the majority of those occurring in patients with lung, breast and colorectal cancers, melanoma, and renal cell carcinoma. Brain metastases are thought to occur via seeding of circulating tumour cells into the brain microvasculature; within this unique microenvironment, tumour growth is promoted and the penetration of systemic medical therapies is limited.

Development of brain metastases remains a substantial contributor to overall cancer mortality in patients with advanced-stage cancer, as prognosis remains poor despite multimodal treatments and advances in systemic therapies, which include a combination of surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapies. This has driven continued development of novel immunotherapies and targeted therapies that have higher bioavailability beyond the blood–tumour barrier, to further advances in radiotherapies and minimally invasive surgical techniques.

As these discoveries and innovations move from the realm of basic science to preclinical and clinical applications, future outcomes for patients with brain metastases are almost certain to improve. In this virtual presentation, we will explore combination trials in solid tumor brain metastases, highlighting the unmet needs in this patient population and underlining promising combination strategies. 

Biography:

Dr. Morganna Vance is a Medical Director within the Melanoma Medical Affairs division at Novartis US Oncology, currently overseeing the conduct of Phase II-III trials in melanoma brain metastases. Dr. Vance is a skin cancer specialist & former Medical Director of Community Practice at City of Hope, an internationally recognized Comprehensive Cancer Center. A recipient of the 2018 Melanoma Research Foundation Humanitarian Award, Dr. Vance contributes regularly as an invited speaker, serves on cancer prevention advisory boards, and is a skilled health policy analyst.

Useful Links

News

Oncology News

2019-11-27

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Oncology News

2019-11-28

Cancer is a condition where cells in a particular part of the body develop and reproduce uncontrollably. The cancerous cells can invade and destroy neighboring healthy tissue, including organs. There are over 200 various types of cancer, each with its method of diagnosis and treatment. In many cases, your symptoms will not be related to cancer and will be caused by other, non-cancerous health conditions.

Global Summit on Neuro Oncology and Leukemia

2019-11-29

This week, the FDA announced 2 new approvals for the treatment of patients with multiple myeloma as well as for detecting minimal residual disease in patients with acute lymphoblastic leukemia or multiple myeloma. A roundup of all the FDA news from September 2018 is also now available. During a Targeted Oncology live case-based peer perspectives presentation, Rachel Sanborn, MD, director of Thoracic Oncology, Providence Cancer Center, discussed treatment options for patients with non—small cell lung cancer (NSCLC). In an interview, Javier A. Pinilla-Ibarz, MD, PhD, a senior member of Moffitt Cancer Center, discussed the current treatment landscape for chronic lymphocytic leukemia, as well as some ongoing research in the field. The top video this week included Fabrice Barlesi, MD, head of the Multidisciplinary Oncology and Therapeutic Innovations Department at Aix-Marseille University and the Assistance Publique Hôpitaux de Marseille, France, where he discussed the importance of molecular testing in patients with NSCLC.

Global Summit on Neuro Oncology and Leukemia

2019-11-30

New cancer-driving mutation in 'dark matter' of the cancer genome Change in just one letter of DNA code in a gene conserved through generations of evolution can cause multiple types of cancer Date: October 9, 2019 Source: Ontario Institute for Cancer Research Summary: A research group has discovered a novel cancer-driving mutation in the vast non-coding regions of the human cancer genome, also known as the 'dark matter' of human cancer DNA.

Global Summit on Neuro Oncology and Leukemia

2019-12-02

Scientists have used single-cell RNA analysis to find that supercentenarians -- meaning people over the age of 110 -- have an excess of a type of immune cell called cytotoxic CD4 T-cells.

Global Summit on Neuro Oncology and Leukemia

2019-12-03

The inability to get human blood stem cells, or hematopoietic stem cells (HSCs), to self-renew in the laboratory is holding back progress in treating leukemia and other blood diseases.

Proton therapy as effective as standard radiation with fewer side effects

2019-12-28

ancer patients who receive high-tech proton therapy experience similar cure rates and fewer serious side effects compared with those who undergo traditional X-ray radiation therapy, according to a study led by Washington University School of Medicine in St. Louis and the Perelman School of Medicine at the University of Pennsylvania. The reduction in side effects -- particularly lower hospitalization rates and fewer emergency room visits -- could offset the higher initial cost of proton therapy, which often is not covered by private insurance because of its higher upfront expense and limited data on its effectiveness compared to X-ray radiation, according to the researchers.

World experts and funders set priorities for COVID-19 research

2020-03-12

Leading health experts from around the world have been meeting at the World Health Organization’s Geneva headquarters to assess the current level of knowledge about the new COVID-19 disease, identify gaps and work together to accelerate and fund priority research needed to help stop this outbreak and prepare for any future outbreaks. The 2-day forum was convened in line with the WHO R&D Blueprint – a strategy for developing drugs and vaccines before epidemics, and accelerating research and development while they are occurring. “This outbreak is a test of solidarity -- political, financial and scientific. We need to come together to fight a common enemy that does not respect borders, ensure that we have the resources necessary to bring this outbreak to an end and bring our best science to the forefront to find shared answers to shared problems. Research is an integral part of the outbreak response,” said WHO Director-General Dr. Tedros Adhanom Ghebreyesus. “I appreciate the positive response of the research community to join us at short notice and come up with concrete plans and commitment to work together.” The meeting, hosted in collaboration with GloPID-R (the Global Research Collaboration for Infectious Disease Preparedness) brought together major research funders and over 300 scientists and researchers from a large variety of disciplines. They discussed all aspects of the outbreak and ways to control it including the natural history of the virus, its transmission, and diagnosis; animal and environmental research on the origin of the virus, including management measures at the human-animal interface; epidemiological studies; clinical characterization and management of disease caused by the virus; infection prevention and control, including best ways to protect health care workers; research and development for candidate therapeutics and vaccines; ethical considerations for research; and integration of social sciences into the outbreak response.

Coronavirus disease (COVID-19)

2020-03-12

Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. Coronaviruses are zoonotic, meaning they are transmitted between animals and people. Detailed investigations found that SARS-CoV was transmitted from civet cats to humans and MERS-CoV from dromedary camels to humans. Several known coronaviruses are circulating in animals that have not yet infected humans. Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death. Standard recommendations to prevent infection spread include regular hand washing, covering mouth and nose when coughing and sneezing, thoroughly cooking meat and eggs. Avoid close contact with anyone showing symptoms of respiratory illness such as coughing and sneezing.

Newsletter

© 2024 All Rights Reserved by Longdom